# EDGAR Filing Document

**Accession Number:** 0001434647
**File Stem:** 0001437749-23-005536
**Filing Date:** 2023-3
**Character Count:** 4779
**Document Hash:** 1dac8cd2c895a32c9e323c92e3e3e4bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-005536.hdr.sgml**: 20230526

**ACCESSION NUMBER**: 0001437749-23-005536

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZEVRA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001434647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 205894398
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1180 CELEBRATION BOULEVARD, SUITE 103
- **CITY:** CELEBRATION
- **STATE:** FL
- **ZIP:** 34747
- **BUSINESS PHONE:** (321) 939-3416

**MAIL ADDRESS:**
- **STREET 1:** 1180 CELEBRATION BOULEVARD, SUITE 103
- **CITY:** CELEBRATION
- **STATE:** FL
- **ZIP:** 34747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEMPHARM, INC
- **DATE OF NAME CHANGE:** 20130530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEMPHARM INC
- **DATE OF NAME CHANGE:** 20080507

![resized1.jpg](resized1.jpg)

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Mergers Acquisitions

100 F Street, N.E.

Washington, D.C. 20549-6010

March 6, 2023

---

| | |
|:---|:---|
| Attention: | Michael Killoy |
|  | Christina Chalk |
| Re: | Zevra Therapeutics, Inc. |
|  | Preliminary Proxy Statement on Schedule 14A |
|  | Filed February 27, 2023 |
|  | File No. 001-36913 |

---

Dear Mr. Killoy and Ms. Chalk:

We respectfully set forth below our responses to the comments of the staff of the Securities and Exchange Commission (the "***Staff***") communicated in its letter addressed to the Zevra Therapeutics, Inc., a Delaware corporation ("***we***," "***us***," "***our***," or the "***Company***"), dated March 3, 2023. For ease of reference, each of the Staff's comments are reproduced below in bold and are followed by the Company's responses.

**<u>Preliminary Proxy Statement on Schedule 14A filed February 27, 2023</u>**

**<u>When are stockholder proposals and director nominations due for next year</u>**<u>'</u>**<u>s annual meeting?, page 10</u>**

<u>Staff Comment</u>: ***1. Please provide the disclosure required by Rule 14a-5(e)(4). See Item 1(c) of Schedule 14A and Rule 14d-19(b).***

<u>Company Response</u>: We acknowledge the Staff's comment and respectfully advise the Staff that, consistent with Rule 14a-19(b) and the Staff's guidance in Compliance and Disclosure Interpretation 139.03, we have revised our preliminary proxy statement (the "***proxy statement***") to clarify that the Rule 14a-5(e)(4) deadline will be the same date as the deadline for submissions of director nominations under the Company's advance notice bylaws. Specifically, we have added the following bolded disclosure on page 10 of the proxy statement, with the actual deadline to be added in our definitive proxy statement:

"In addition to satisfying the foregoing requirements under our bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must provide notice that sets forth the information required by Rule 14a-19**(b)** under the Exchange Act **by the deadline for submitting director nominations under our bylaws, as described in the paragraph above.**"

------

![resized1.jpg](resized1.jpg)

**<u>Annex A. Information Concerning Participants in the Company</u>**<u>'</u>**<u>s Solicitation of Proxies, page A-1</u>**

<u>Staff Comment</u>: ***Please disclose the information required by Item 5(b)(1)(iii) of Schedule 14A, which requires you to disclose whether or <u>not</u> any of the specified individuals have been involved in any proceedings.***

<u>Company Response</u>: We acknowledge the Staff's comment and respectfully advise the Staff that we have revised Annex A of the proxy statement to provide the required disclosure.

**<u>General</u>**

Staff Comment: ***3. For proposals 2 and 3, please disclose the effect of an*** "***ABSTAIN***" ***vote. See Item 21(b) of Schedule 14A.***

Company Response: We acknowledge the Staff's comment and advise the Staff that we have revised page 9 of the proxy statement to provide the required disclosure.

If you require additional information or have any questions about this letter, please call me at (321) 939-3416.

Sincerely,

<u>/s/ R. LaDuane Clifton</u>

R. LaDuane Clifton

Chief Financial Officer

Zevra Therapeutics, Inc.

---

| | |
|:---|:---|
| CC (via email): | Richard W. Pascoe, Chief Executive Officer, Zevra Therapeutics, Inc. |
|  | Nathan Ajiashvili, Latham & Watkins LLP |
|  | Joshua M. Dubofsky, Latham & Watkins LLP |
|  | Jenna B. Cooper, Latham & Watkins LLP |

---